ArticleThe British journal of dermatology2023
Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment.
Article in The British journal of dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Dupilumab for the Treatment of Cutaneous Immune-Related Adverse Events: A Systematic Review.International journal of dermatology · 2025Pooled it
- An atypical presentation of Pembrolizumab-induced bullous pemphigoid in a patient with uterine serous carcinoma.Gynecologic oncology reports · 2026Article
- Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.Drugs · 2026Review
- Efficacy and safety of biologic therapies in immune checkpoint inhibitor-induced bullous pemphigoid.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case Series.Acta dermato-venereologica · 2026Observational
- A case series of immune checkpoint inhibitor-induced bullous pemphigoid successfully treated with dupilumab and evidence for the BP180 midportion epitope as a preferential autoantigenic target.Frontiers in medicine · 2026Article
- Immuno-oncologyDupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series.The oncologist · 2025Article
- Immune checkpoint inhibitor induced bullous pemphigoid treated by dupilumab: A case series.JAAD case reports · 2025Article
- A case of pembrolizumab-induced bullous pemphigoid treated with dupilumab.Skin health and disease · 2025Article
- A Case Report of Tislelizumab-Induced Lichen Planus Pemphigoides.Clinical, cosmetic and investigational dermatology · 2025Article
- [Skin fragility in autoimmune blistering diseases of the skin].Dermatologie (Heidelberg, Germany) · 2024Review
- Treatment of immune checkpoint inhibitor-induced bullous pemphigoid with methotrexate.JAAD case reports · 2024Article
- Cancer Therapy-induced Dermatotoxicity as a Window to Understanding Skin Immunity.Hematology/oncology clinics of North America · 2024Review
- Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.The Journal of clinical investigation · 2024Observational
- The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.American journal of clinical dermatology · 2024Review
- Severe cutaneous adverse reactions.Nature reviews. Disease primers · 2024Review
- Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy.The British journal of dermatology · 2023Article
- Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches.Clinical reviews in allergy & immunology · 2023Review
- Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.